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A B S T R A C T
Background
Mannitol is sometimes dramatically effective in reversing acute brain swelling, but its effectiveness in the on-going management of
severe head injury remains open to question. There is evidence that, in prolonged dosage, mannitol may pass from the blood into the
brain, where it might cause reverse osmotic shifts that increase intracranial pressure.
Objectives
To assess the effects of different mannitol therapy regimens, of mannitol compared to other intracranial pressure (ICP) lowering agents,
and to quantify the effectiveness of mannitol administration given at other stages following acute traumatic brain injury.
Search strategy
The review drew on the search strategy for the Injuries Group as a whole. We checked reference lists of trials and review articles, and
contacted authors of trials.
Selection criteria
Randomised trials of mannitol, in patients with acute traumatic brain injury of any severity. The comparison group could be placebo-
controlled, no drug, different dose, or different drug. Trials where the intervention was started more than eight weeks after injury, and
cross-over trials were excluded.
Data collection and analysis
The reviewers independently rated quality of allocation concealment and extracted the data. Relative risks (RR) and 95% confidence
intervals (CI) were calculated for each trial on an intention to treat basis.
Main results
Overall therewere few eligible trials. In the pre-operativemanagement of patientswith acute intracranial haemorrhage the administration
of high-dose mannitol resulted in reduced mortality (RR=0.55; 95%CI 0.36, 0.84) and reduced death and severe disability (RR=0.58;
95%CI 0.45, 0.74) when compared with conventional-dose mannitol. One trial compared ICP-directed therapy to ’standard care’ (RR
for death= 0.83; 95%CI 0.47,1.46). One trial compared mannitol to pentobarbital (RR for death = 0.85; 95% CI 0.52, 1.38). No
trials compared mannitol to other ICP-lowering agents. One trial tested the effectiveness of pre-hospital administration of mannitol
against placebo (RR for death=1.75; 95% CI 0.48, 6.38).
1Mannitol for acute traumatic brain injury (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors’ conclusions
High-dose mannitol appears to be preferable to conventional-dose mannitol in the pre-operative management of patients with acute
intracranial haematomas. However, there is little evidence about the use of mannitol as a continuous infusion in patients with raised
intracranial pressure in patients who do not have an operable intracranial haematoma. Mannitol therapy for raised ICP may have
a beneficial effect on mortality when compared to pentobarbital treatment. ICP-directed treatment shows a small beneficial effect
compared to treatment directed by neurological signs and physiological indicators. There are insufficient data on the effectiveness of
pre-hospital administration of mannitol to preclude either a harmful or a beneficial effect on mortality.
P L A I N L A N G U A G E S U M M A R Y
Synopsis
There is evidence that mannitol can improve outcomes after severe head injury, but more research is needed on how best to use it, as it
can also cause problems
Severe head injury can lead to brain swelling. As space inside the skull is limited, this can cause dangerous pressure on the brain (raised
intracranial pressure - ICP). Mannitol reverses the swelling at first, but there is evidence that its prolonged use can eventually worsen the
pressure. The review found there is not enough evidence from trials to show how best to use mannitol for people with head injury. For
people with raised ICP, mannitol may reduce the chances of death more than pentobarbital (a barbiturate drug). There is not enough
evidence to show whether giving mannitol before head-injured people arrive in hospital can improve outcomes.
B A C K G R O U N D
Mannitol is widely used in the control of raised intracranial pres-
sure following brain injury. A 1995 survey of the critical care man-
agement of head-injured patients in the United States showed that
83% of centres used osmotic diuretics in more than half of severely
head-injured patients (Ghajar 1995), a survey in the United King-
dom showed that 100% of neurosurgical centres used mannitol in
the treatment of raised intracranial pressure (Jeevaratnam 1996;
Matta 1996). The effectiveness of mannitol for head-injured pa-
tients in a critical condition is considered to be well established,
without the need for randomised controlled trials.
For other patients, the Brain Trauma Foundation Guidelines Task
force of the American Association of Neurological Surgeons and
Joint Section inNeurotrauma and Critical Care (Task Force 1995)
recommend that mannitol be used only if the patient has signs
of raised ICP or deteriorating neurological status as, in these cir-
cumstances, adverse effects are most likely to be outweighed by
therapeutic benefit. Nevertheless, the guidelines acknowledge that
this is an area of considerable clinical uncertainty. There is uncer-
tainty over the optimal treatment regimen, over the effectiveness
of mannitol as compared to other ICP-lowering agents and over
the usefulness of mannitol given at other stages following head
injury, for example in the pre-hospital setting, prior to volume
resuscitation.
We conducted a systematic review of randomised controlled trials
that compared different mannitol treatment regimens, or com-
paredmannitol to alternative interventions or placebo, at any stage
in the acute management of head injury.
O B J E C T I V E S
1. To compare the effectiveness of mannitol therapy when given
in different doses and for different durations.
2. To quantify the effectiveness of mannitol compared to other
ICP-lowering agents.
3. To quantify the effectiveness of mannitol administration given
at other stages following head injury.
R E S U L T S
One trial compared ICP-directed therapy to ’standard care’ , in
which mannitol therapy was directed by neurological signs (Smith
1986). The study was randomised and allocation concealment was
by the use of sealed envelopes. For ICP-directed treatment com-
pared to treatment based on neurological signs, the RR for death
2Mannitol for acute traumatic brain injury (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
was 0.83 (95% CI 0.47,1.46); this trial demonstrated a similar
effect for death or severe disability (RR=0.88; 95%CI 0.55,1.38).
One trial compared mannitol to pentobarbital (Schwartz 1984).
This trial was randomised and single blind. Only patients with
known raised ICP were included. For mannitol compared to pen-
tobarbital in the treatment of patients with raised ICP, the RR
for death was 0.85 (95%CI 0.52,1.38) . No trials identified that
compared mannitol to other ICP-lowering agents.
The effectiveness of pre-hospital administration of mannitol
against placebo was investigated in Sayre 1996. This study was
randomised and allocation concealment was through pharmacy
prepared blinded solutions. For pre-hospital infusion of mannitol
compared to placebo in patients with head injury and multiple
trauma, the RR for death was 1.75 (95%CI 0.48, 6.38).
Two trials (Cruz 2001; Cruz 2002) compared high-dose and con-
ventional-dose mannitol in the pre-operative acute care of patients
with intracranial haemorrhages. In both studies there were fewer
deaths in the high-dose mannitol group, with a pooled relative risk
of death of 0.55 (95%CI 0.36, 0.84). In both trials, the propor-
tion of patients who were dead or severely disabled at six months
was lower in the high-dose mannitol group, with a pooled relative
risk of death or severe disability of 0.58 (95%CI 0.45, 0.74).
D I S C U S S I O N
There were few eligible trials of mannitol therapy in head-injured
patients.
ICP-directed treatment showed a small beneficial effect on mor-
tality when compared to treatment directed according to neuro-
logical signs and physiological indicators (RR=0.83; 95%CI 0.47,
1.46). Themethod of allocation concealment in this study was ad-
equate to prevent fore-knowledge of treatment, and was unlikely
to have led to bias. Owing to small patient numbers, the effect
measure is imprecise. It must be noted that in this study the ICP-
directed protocol initiated mannitol only when the ICP rose to
above 25mmHg and therefore these results cannot be extrapolated
to ICP-directed protocols which initiate mannitol therapy at a
lower level.
Pre-operative administration of high-dose mannitol results in re-
duced mortality and morbidity compared with conventional-dose
mannitol. However, in both of the eligible trials, allocation con-
cealment was not described and the possibility of selection bias is
open to question.
Mannitol therapy may have a beneficial effect on mortality when
compared topentobarbital therapy.However, the single trial which
tested this (Schwartz 1984) yielded an imprecise effect measure,
which also may be compatible with no difference, or a beneficial
effect of pentobarbital. The trial was testing an initial treatment of
mannitol compared topentobarbital as some patients later received
the alternate therapy if the allocated therapy failed to control ICP.
There were no trials of mannitol compared to other ICP-lowering
interventions.
The single trial which compared pre-hospital administration of
mannitol to placebo showed an increase in mortality amongst
the mannitol-treated patients (RR=1.75; 95%CI 0.48, 6.38). The
estimate yielded by this trial is imprecise owing to the small sample
size; the effect measure also may be compatible with no difference,
or a beneficial effect of pre-hospital administration of mannitol.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
High-dose mannitol appears to be preferable to conventional-dose
mannitol in the pre-operative management of patients with acute
intracranial haematomas. However, there is little evidence about
the use of mannitol as a continuous infusion in patients with
raised intracranial pressure in patients who do not have an operable
intracranial haematoma.
Implications for research
There aremany unanswered questions regarding the optimal use of
mannitol following acute traumatic head injury. The widespread
current use of mannitol, and lack of clarity regarding optimal
administration present an ideal opportunity for the conduct of
randomised controlled trials.
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